Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study
Abstract Background Coronary artery disease (CAD) is considered as a multi-faceted chronic inflammatory disease involving reduced blood supply to the myocardium as a result of accumulating lipids in the atrial walls. Visceral adiposity with disrupted release of adipokines play a key role in its path...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-08-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12944-021-01514-9 |
id |
doaj-12d6b8dd607a464e9367e16f7ede52f8 |
---|---|
record_format |
Article |
spelling |
doaj-12d6b8dd607a464e9367e16f7ede52f82021-08-22T11:45:10ZengBMCLipids in Health and Disease1476-511X2021-08-012011810.1186/s12944-021-01514-9Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control studyNariman Moradi0Fatima Zahraa Fouani1Akram Vatannejad2Abbas Bakhti Arani3Soraya Shahrzad4Reza Fadaei5Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical SciencesDepartment of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical SciencesDepartment of Comparative Biosciences, Faculty of Veterinary Medicine, University of TehranDepartment of Cardiology, Dr Shariatee training and research Hospital, Tehran University of Medical SciencesDepartment of Cardiology, Dr Shariatee training and research Hospital, Tehran University of Medical SciencesSleep Disorders Research Center, Kermanshah University of Medical SciencesAbstract Background Coronary artery disease (CAD) is considered as a multi-faceted chronic inflammatory disease involving reduced blood supply to the myocardium as a result of accumulating lipids in the atrial walls. Visceral adiposity with disrupted release of adipokines play a key role in its pathogenesis. Asprosin is a newly identified fasting-induced glucogenic adipokine that has been related with metabolic disorders such as type II diabetes mellitus and polycystic ovary syndrome. The preset study sought to assess circulating asprosin in context of CAD. Methods In this study, serum levels of asprosin were determined in 88 CAD patients and 88 non-CAD healthy controls. Serum IL-6, TNF-α, asprosin and adiponectin were assessed using ELISA kits. Results: Serum asprosin was found to be higher in CAD patients when compared to non-CAD subjects (7.84 ± 2.08 versus 5.02 ± 1.29 μg/mL, p < 0.001). Similarly, serum TNF-α, and IL-6 elevated in CAD group significantly (p < 0.001). However, circulating adiponectin diminished in CAD group when compared with non-CAD subjects (p < 0.001). Moreover, serum asprosin levels directly correlated with BMI, FBG, HOMA-IR, TG and TC. Logistic regression analyses showed that asprosin levels were associated with increased risk of developing CAD (odds ratio: 3.01, 95% CI: 2.16, 4.20 and p < 0.001), after adjusting for potential confounders (age, sex and BMI). Conclusions The present study findings suggested a possible relation of serum asprosin with the pathogenesis of CAD, in particular through insulin resistance and dyslipidemia.https://doi.org/10.1186/s12944-021-01514-9Coronary artery diseaseAsprosinInsulin resistanceDyslipidemiaAdipokine |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nariman Moradi Fatima Zahraa Fouani Akram Vatannejad Abbas Bakhti Arani Soraya Shahrzad Reza Fadaei |
spellingShingle |
Nariman Moradi Fatima Zahraa Fouani Akram Vatannejad Abbas Bakhti Arani Soraya Shahrzad Reza Fadaei Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study Lipids in Health and Disease Coronary artery disease Asprosin Insulin resistance Dyslipidemia Adipokine |
author_facet |
Nariman Moradi Fatima Zahraa Fouani Akram Vatannejad Abbas Bakhti Arani Soraya Shahrzad Reza Fadaei |
author_sort |
Nariman Moradi |
title |
Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study |
title_short |
Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study |
title_full |
Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study |
title_fullStr |
Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study |
title_full_unstemmed |
Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study |
title_sort |
serum levels of asprosin in patients diagnosed with coronary artery disease (cad): a case-control study |
publisher |
BMC |
series |
Lipids in Health and Disease |
issn |
1476-511X |
publishDate |
2021-08-01 |
description |
Abstract Background Coronary artery disease (CAD) is considered as a multi-faceted chronic inflammatory disease involving reduced blood supply to the myocardium as a result of accumulating lipids in the atrial walls. Visceral adiposity with disrupted release of adipokines play a key role in its pathogenesis. Asprosin is a newly identified fasting-induced glucogenic adipokine that has been related with metabolic disorders such as type II diabetes mellitus and polycystic ovary syndrome. The preset study sought to assess circulating asprosin in context of CAD. Methods In this study, serum levels of asprosin were determined in 88 CAD patients and 88 non-CAD healthy controls. Serum IL-6, TNF-α, asprosin and adiponectin were assessed using ELISA kits. Results: Serum asprosin was found to be higher in CAD patients when compared to non-CAD subjects (7.84 ± 2.08 versus 5.02 ± 1.29 μg/mL, p < 0.001). Similarly, serum TNF-α, and IL-6 elevated in CAD group significantly (p < 0.001). However, circulating adiponectin diminished in CAD group when compared with non-CAD subjects (p < 0.001). Moreover, serum asprosin levels directly correlated with BMI, FBG, HOMA-IR, TG and TC. Logistic regression analyses showed that asprosin levels were associated with increased risk of developing CAD (odds ratio: 3.01, 95% CI: 2.16, 4.20 and p < 0.001), after adjusting for potential confounders (age, sex and BMI). Conclusions The present study findings suggested a possible relation of serum asprosin with the pathogenesis of CAD, in particular through insulin resistance and dyslipidemia. |
topic |
Coronary artery disease Asprosin Insulin resistance Dyslipidemia Adipokine |
url |
https://doi.org/10.1186/s12944-021-01514-9 |
work_keys_str_mv |
AT narimanmoradi serumlevelsofasprosininpatientsdiagnosedwithcoronaryarterydiseasecadacasecontrolstudy AT fatimazahraafouani serumlevelsofasprosininpatientsdiagnosedwithcoronaryarterydiseasecadacasecontrolstudy AT akramvatannejad serumlevelsofasprosininpatientsdiagnosedwithcoronaryarterydiseasecadacasecontrolstudy AT abbasbakhtiarani serumlevelsofasprosininpatientsdiagnosedwithcoronaryarterydiseasecadacasecontrolstudy AT sorayashahrzad serumlevelsofasprosininpatientsdiagnosedwithcoronaryarterydiseasecadacasecontrolstudy AT rezafadaei serumlevelsofasprosininpatientsdiagnosedwithcoronaryarterydiseasecadacasecontrolstudy |
_version_ |
1721199397928173568 |